Parkinson’s disease
Conditions
Interventions
Butylphthalide group and Control group:Butylphthalide 200mg/time(2 capsules) , three time/day, for 24 weeks
Sponsors
The Second Affiliated Hospital of Soochow University
Eligibility
Sex/Gender
All
Age
35 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Meet the clinical diagnostic criteria for primary Parkinsons disease and require at least 2 of the cardinal motor manifestations (bradykinesia, tremor or rigidity). Clearly not attributable to other secondary parkinsonism; 2. Modified H-Y stage < 3; 3. Aged 35 years old and elder; 4. Stability of symptoms and signs over 1month or more; 5. MDS-UPDRS Part III score = 10 at baseline; 6. Dose of levodopa daily=300mg; 7. An informed consent has been signed by the patient himself/herself before the study.
Exclusion criteria
Exclusion criteria: 1. Hepatic function abnormality (ALT/AST >1.5 times ULL), renal function abnormality (Cre>2.0mg/dl or 177 umol/L), cardiac dysfunction or with other severe systemic disease; 2. With occurrence of any malignancy or under oncotherapy; 3. Being allergic to celery or Butylphthalide; 4. Patient who is within the gestation period or have any possibility or intention to get pregnant; 5. Have been involved in other intervention study in the last 3 months or is now under other intervention study; 6. Patients, considered by the investigators, who is not suitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| UPDRS (UPDRS part I + II + III);portable device evaluation; | — |
Countries
China
Contacts
Public ContactLiu Chunfeng
The Second Affiliated Hospital of Soochow University
Outcome results
None listed